HIV drug resistance

[1] Access and activism: the ethics of providing antiretroviral therapy in developing countries [J]. AIDS, 2001, 15 : S81 - S90

[2] [Anonymous], 2003, SCAL ANT THER RES LT

[3] Clavel F, 2004, NEW ENGL J MED, V350, P1023, DOI 10.1056/NEJM2ra025195

[4] Medecins Sans Frontieres, 2003, UNT WEB PRIC RED PRI

[5] Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study [J]. LANCET, 2004, 363 (9417) : 1253 - 1263

[1] Access and activism: the ethics of providing antiretroviral therapy in developing countries [J]. AIDS, 2001, 15 : S81 - S90

[2] [Anonymous], 2003, SCAL ANT THER RES LT

[3] Clavel F, 2004, NEW ENGL J MED, V350, P1023, DOI 10.1056/NEJM2ra025195

[4] Medecins Sans Frontieres, 2003, UNT WEB PRIC RED PRI

[5] Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study [J]. LANCET, 2004, 363 (9417) : 1253 - 1263